Lipid profile in people starting antiretroviral therapy with efavirenz or dolutegravir based regimens from a reference center in Brazil: a cohort study
DOI:
https://doi.org/10.33448/rsd-v11i5.28662Keywords:
Dyslipidemia; Antiretroviral Therapy, Highly Active; HIV Integrase Inhibitors; Reverse Transcriptase Inhibitors.Abstract
Objective: To compare the impact on lipid profile (LP) in people starting antiretroviral therapy (ART) before e after the use with efavirenz (EFZ) or dolutegravir (DTG) based regimens. Methods: A prospective cohort study stratified into two groups, the people living with HIV (PLWHIV) who started either DTG or EFV. Dyslipidemia was defined by laboratory criteria in the period from September 2015 to October 2017. Parametric and non-parametric tests and matched pair tests were used, considering p <0.05 statistically significant. Results: Studied 468 individuals stratified into two groups, with (n=180) or without (n=288) records of laboratory tests at time T0 (start of treatment) or at T48 (12 months after the dispensation of antiretroviral drugs. Among these 180, 60 (33.1%) were taking DTG and 113 (62.4%) were taking EFZ. In comparisons of serum PL level (mg/dl), pre and post ART, all values showed an increase and statically significant for HDL (p<0.001). The variation of PL was analyzed, post TARV and in relation to the use of EFV and DTG. In relation to EFZ, there was an increase in the serum level of the whole PL, statically significant for HDL. Regarding DTG, there was increase in serum level only for VLDL which was not statically significant. Conclusion: Comparing the use of DTG with EFV, EFV increased the serum level of TC and fractions, statically significant for HDL. With the use of DTG, there was an increase in serum VLDL level and decrease in HDL-C, without statistical significance.
References
Almeida, E. (2016, June 9). Declaração Política de 2016 da ONU sobre o Fim da AIDS. UNAIDS Brasil. https://unaids.org.br/2016/06/declaracao-politica-2016-ps
Brasil. (2018). Protocolo clínico e diretrizes terapêuticas para o manejo da infecção pelo hiv em adultos. Ministério da Saúde. Secretaria de Vigilância em Saúde (1st ed., p. 410). http://www.aids.gov.br/pt-br/pub/2013/protocolo-clinico-e-diretrizes-terapeuticas-para-manejo-da-infeccao-pelo-hiv-em-adultos
Braunwald et al (2016). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in. (2001). Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA: The Journal of the American Medical Association, 285(19), 2486–2497. https://doi.org/10.1001/jama.285.19.2486
Doenças cardiovasculares continuam sendo principal causa de morte nas Américas. (n.d.). Paho.org. Retrieved 27 March 2022, from https://www.paho.org/pt/noticias/29-9-2021-doencas-cardiovasculares-continuam-sendo-principal-causa-morte-nas-americas
Faludi, A. A., Izar, M. C. O., Saraiva, J. F. K., Chacra, A. P. M., Bianco, H. T., Afiune Neto, A, Bertolami, A., Pereira, A. C., Lottenberg, A. M. P., Sposito, A. C., Chagas, A. C. P, Casella-Filho, A., Simão, A. F., Alencar Filho, A. C., Caramelli, B., Magalhães, C. C., Magnoni, D., Negrão, C. E., Ferreira, C. E. S., Salgado Filho, W. (2017). Atualização Da diretriz brasileira DE dislipidemias e prevenção Da aterosclerose - 2017. Arquivos Brasileiros de Cardiologia, 109(1). https://doi.org/10.5935/abc.20170121
Feinstein, M. J., Hsue, P. Y., Benjamin, L. A., Bloomfield, G. S., Currier, J. S., Freiberg, M. S., Grinspoon, S. K., Levin, J., Longenecker, C. T., & Post, W. S. (2019). Characteristics, prevention, and management of cardiovascular disease in people living with HIV: A scientific statement from the American heart association. Circulation, 140(2), e98–e124. https://doi.org/10.1161/CIR.0000000000000695
Freiberg, M. S., Chang, C.-C. H., Skanderson, M., Patterson, O. V., DuVall, S. L., Brandt, C. A., So-Armah, K. A., Vasan, R. S., Oursler, K. A., Gottdiener, J., Gottlieb, S., Leaf, D., Rodriguez-Barradas, M., Tracy, R. P., Gibert, C. L., Rimland, D., Bedimo, R. J., Brown, S. T., Goetz, M. B., Butt, A. A. (2017). Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: Results from the Veterans Aging Cohort Study. JAMA Cardiology, 2(5), 536–546. https://doi.org/10.1001/jamacardio.2017.0264
Gillette, M. A., Shah, B. M., Schafer, J. J., & DeSimone, J. A., Jr. (2014). Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV - an alternative viewpoint. Pharmacotherapy, 34(9), e173-4. https://doi.org/10.1002/phar.1478
Hajjar, L. A., Calderaro, D., Yu, P. C., Giuliano, I., Lima, E. M. de O., Barbaro, G., & Caramelli, B. (2005). Cardiovascular manifestations in patients infected with the human immunodeficiency virus. Arquivos brasileiros de cardiologia, 85(5), 363–377. https://doi.org/10.1590/s0066-782x2005001800013
Kandel, C. E., & Walmsley, S. L. (2015). Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV. Drug Design, Development and Therapy, 9, 3547–3555. https://doi.org/10.2147/DDDT.S84850
Kelesidis, T., & Currier, J. S. (2014). Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection. Endocrinology and Metabolism Clinics of North America, 43(3), 665–684. https://doi.org/10.1016/j.ecl.2014.06.003
Nou, E., Lo, J., & Grinspoon, S. K. (2016). Inflammation, immune activation, and cardiovascular disease in HIV. AIDS (London, England), 30(10), 1495–1509. https://doi.org/10.1097/QAD.0000000000001109
Précoma, D. B. (2019). Atualização da Diretriz de Prevenção Cardiovascular da Sociedade Brasileira de Cardiologia. https://doi.org/:10.5935/abc.20190204
Quercia, R., Roberts, J., Martin-Carpenter, L., & Zala, C. (2015). Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clinical Drug Investigation, 35(3), 211–219. https://doi.org/10.1007/s40261-014-0266-2
Raffi, F., Rachlis, A., Stellbrink, H.-J., Hardy, W. D., Torti, C., Orkin, C., Bloch, M., Podzamczer, D., Pokrovsky, V., Pulido, F., Almond, S., Margolis, D., Brennan, C., Min, S., & SPRING-2 Study Group. (2013). Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet, 381(9868), 735–743. https://doi.org/10.1016/S0140-6736(12)61853-4
Rhoads, M. P., Lanigan, J., Smith, C. J., & Lyall, E. G. H. (2011). Effect of specific ART drugs on lipid changes and the need for lipid management in children with HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 57(5), 404–412. https://doi.org/10.1097/QAI.0b013e31821d33be
Rodger, A. J., Lodwick, R., Schechter, M., Deeks, S., Amin, J., Gilson, R., Paredes, R., Bakowska, E., Engsig, F. N., Phillips, A., & INSIGHT SMART, ESPRIT Study Groups. (2013). Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS (London, England), 27(6), 973–979. https://doi.org/10.1097/QAD.0b013e32835cae9c
Shah, B., Schafer, J., & DeSimone, J., Jr. (2014). Dolutegravir: A new integrase strand transfer inhibitor for the treatment of HIV. Pharmacotherapy, 34(6), 667–667. https://doi.org/10.1002/phar.1454
Sinxadi, P. Z., McIlleron, H. M., Dave, J. A., Smith, P. J., Levitt, N. S., Haas, D. W., & Maartens, G. (2016). Plasma efavirenz concentrations are associated with lipid and glucose concentrations. Medicine, 95(2), e2385. https://doi.org/10.1097/md.0000000000002385
van Lunzen, J., Maggiolo, F., Arribas, J. R., Rakhmanova, A., Yeni, P., Young, B., Rockstroh, J. K., Almond, S., Song, I., Brothers, C., & Min, S. (2012). Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. The Lancet Infectious Diseases, 12(2), 111–118. https://doi.org/10.1016/S1473-3099(11)70290-0
Williams, P., Wu, J., Cohn, S., Koletar, S., McCutchan, J., Murphy, R., Currier, J., & AIDS Clinical Trials Group 362 Study Team. (2009). Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution. HIV Medicine, 10(5), 290–301. https://doi.org/10.1111/j.1468-1293.2008.00685.x
Worm, S. W., Sabin, C., Weber, R., Reiss, P., El-Sadr, W., Dabis, F., De Wit, S., Law, M., Monforte, A. D., Friis-Møller, N., Kirk, O., Fontas, E., Weller, I., Phillips, A., & Lundgren, J. (2010). Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D: A:D) study. The Journal of Infectious Diseases, 201(3), 318–330. https://doi.org/10.1086/649897
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Ana Cristina da Silva Fernandes; Jorgino Júlio Cesar; Palmira de Fátima Bonolo; Clessius Ribeiro de Souza; Maria das Graças Braga Ceccato
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
